Vandetanib: In medullary thyroid cancer

Drugs

Volumn 72, Issue 10, 2012, Pages 1423-1436

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Thyroid cancer; Vandetanib

Indexed keywords

ANTIARRHYTHMIC AGENT; ARSENIC; BORTEZOMIB; CALCITONIN; CARBAMAZEPINE; CARCINOEMBRYONIC ANTIGEN; CISAPRIDE; CLARITHROMYCIN; CREATININE; CYCLOSPORIN; DABIGATRAN; DIGOXIN; DOCETAXEL; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; METFORMIN; MIZOLASTINE; MOXIFLOXACIN; ONDANSETRON; PHENYTOIN; PLACEBO; PROTEIN RET; PROTON PUMP INHIBITOR; RIFAMPICIN; RITONAVIR; TACROLIMUS; TOREMIFENE; VANDETANIB;

ACNE; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APPETITE; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; CALCIUM BLOOD LEVEL; CANCER CONTROL; CANCER SURVIVAL; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DERMATITIS; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; ERYTHEMA MULTIFORME; EXON; FAMILIAL CANCER; FATIGUE; FOLLOW UP; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IC 50; INTERSTITIAL LUNG DISEASE; KIDNEY FUNCTION; LEUKOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; PAIN; PHOTOSENSITIVITY; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THYOID MEDULLARY CANCER; THYROID CANCER; THYROID MEDULLARY CANCER; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR STRUCTURE; NEOPLASM METASTASIS; PIPERIDINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROID NEOPLASMS;

EID: 84863197764     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209300-000000000-00000     Document Type: Article

References (49)

1. Sharma PK. Thyroid cancer [online]. Available from URL: http://emedicine.medscape.com/article/851965-overview [Accessed 2012 Feb 23]
2. Cancer Research UK. Thyroid cancer: UK incidence statistics [online]. Available from URL: http://info.cancer researchuk.org/cancerstats/types/thyroid/ incidence/ukthyroid-cancer-incidence-statistics [Accessed 2012 Feb 22]
3. Pitt SC, Moley JF. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol 2010 Dec; 37 (6): 567-79
4. Houvras Y. Completing the arc: targeted inhibition of RET in medullary thyroid cancer. J Clin Oncol 2012 Jan 10; 30 (2): 200-2
5. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol 2007 Jan; 19 (1): 18-23 (Pubitemid 44885595)
6. Quale FJ, Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. Curr Treat Options Oncol 2005; 6 (4): 347-54 (Pubitemid 41223388)
7. Gomez K, Varghese J, Jimenez C, et al. MTC: molecular signaling pathways and emerging therapies. J Thyroid Res 2011; 815-26
8. Moley J. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw 2010; 8: 549-56
9. SippelRS, KunnimalaiyaanM, ChenH. Current management of medullary thyroid cancer. Oncologist 2008; 13: 539-47 (Pubitemid 351872871)
10. Rodŕquez-Antona C, Pallares J, Montero-Conde C, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010; 17: 7-16
11. Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol 2011 May; 9 (5): 391-4
12. Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments. Curr Opin Oncol 2011 Jan; 23 (1): 22-7
13. Schlumberger M, Carlomagno F, Baudin E, et al. New therapeutic approaches to treat medullary thyroid cancer. Nat Clin Pract Endocrinol Metab 2007; 4 (1): 22-32
14. Orlandi F, Caraci P, Mussa A, et al. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 2001; 8: 135-47 (Pubitemid 32641355)
15. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Assocation. Thyroid 2009 Jun; 19 (6): 565-612
16. Gild ML, Bullock M, Robinson BG, et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011 Oct; 7 (10): 617-24
17. Antonelli A, Fallahi P, Ferrari SM, et al. RET TKI: potential role in thyroid cancers. Curr Oncol Rep 2012 Jan 28
18. Commander H, Whiteside G, Perry C. Vandetanib: first global approval. Drugs 2011; 71 (10): 1355-65
19. AstraZeneca AB. Caprelsa 100 mg and 300 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.medicines. org.uk [Accessed 2012 Mar 22]
20. Caprelsa(vandetanib) tablets: US prescribing information [online]. Available from URL: http://www1.astrazenecaus. com/pi/vandetanib.pdf [Accessed 2012 Feb 27]
21. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002 Aug 15; 62 (16): 4645-55
22. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62 (24): 7284-90 (Pubitemid 36025251)
23. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004; 23 (36): 6056-63 (Pubitemid 39178858)
24. Carlomagno F, Guida T, Anaganti S, et al. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocr Relat Cancer 2009; 16: 233-41
25. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer.NEngl J Med 2003 Oct 16; 349 (16): 1517-25 (Pubitemid 37255037)
26. Broutin S, Dupuy C, Caillou B, et al. In vitro and in vivo activity of vandetanib in a human medullary thyroid carcinoma model bearing a RET(C634W) activating mutation (abstract no. 1788). 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver (CO)
27. Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 2011 Feb; 18 (1): 1-11
28. Wu W, Isobe T, Onn A, et al. Targeted therapy against VEGF and EGF receptor signalling with ZD6474 blocks angiogenesis and inhibits the growth and dissemination of orthotopic human lung cancer in mice. Clin Cancer Res 2003; 9 (Pt. 2): 6143s
29. Drevs J, Konerding MA, Wolloscheck T, et al. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004; 7 (4): 347-54 (Pubitemid 40767936)
30. McCarty MF, Whey J, Stoeltzing O, et al. ZD6474, a dual tyrosine kinase inhibitor with activity against VEGF-R and EGF-R, inhibits orthotopic growth and angiogenesis of gastric cancer. Clin Cancer Res 2003; 9 (Pt 2): 6140s
31. Bruns CJ, Kö hl G, Guba M, et al. Anti-angiogenic and antitumour activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumour model. Proc Am Soc Cancer Res (2nd ed) 2003; 44: 604
32. Wu W, Isobe T, Itasaka S, et al. ZD6474, a small molecule targetting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. Proc Am Assoc Cancer Res 2004; 45: 1051
33. Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004 Dec 15; 64: 9101-4 (Pubitemid 39665524)
34. Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci 2004 Dec; 95 (12): 984-9 (Pubitemid 40089591)
35. Gule MK, Chen Y, Sano D, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 2011 Apr 15; 17 (8): 2281-91
36. Ryan AJ, Wedge SR. ZD6474: a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92 Suppl. 1: S6-13 (Pubitemid 40897411)
37. BrassardM, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin EndocrinolMetab 2011; 96 (9): 2741-9
38. Center for Drug Evaluation and Research. Application number: 022405Orig1s000. Pharmacology review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfdadocs/nda/2011/022405Orig1s000PharmR.pdf [Accessed 2012 Feb 29]
39. European Medicines Agency. Assessment report. Caprelsa. Vandetanib. Procedure no. EMEA/H/C/002315//0000 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002315/WC500123603.pdf [Accessed 2012 Feb 29]
40. Wells SA, Robinson BG, Gagel RF. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012 Jan 10; 30 (2): 134-41
41. Center for Drug Evaluation and Research. Application number: 022405Orig1s000. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfdadocs/nda/2011/ 022405Orig1s000ClinPharmR.pdf [Accessed 2012 Feb 29]
42. Martin P, Oliver S, Kennedy S-J, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 2012 Jan; 34 (1): 221-37
43. Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet 2010 Sep 1; 49 (9): 607-18
44. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005 Aug; 16 (8): 1391-7 (Pubitemid 41158486)
45. Zhang L, Li S, Zhang Y, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011; 33 (3): 315-27
46. Matin P, Oliver S, Robertson J, et al. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or intraconazole. Drugs R D 2011; 11 (1): 37-51
47. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95 (6): 2664-71
48. Wells Jr SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010 Feb 10; 28 (5): 767-72
49. Langmuir PB, Yver A. Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther 2012; 91 (1): 71-80